Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12778197 | 0.90 | ALDH1A1 (0.73) | TSHRALDH1A1 | |
| SCHEMBL13573035 | 0.87 | TSHR (0.62) | TSHRALDH1A1TDP1NPSR1CA12 | |
| SCHEMBL12310314 | 0.87 | TSHR (0.62) | TSHRALDH1A1TDP1NPSR1CA12 | |
| SCHEMBL12310311 | 0.87 | TSHR (0.62) | TSHRALDH1A1TDP1NPSR1CA12 | |
| SCHEMBL6138380 | 0.84 | TSHR (0.59) | TSHRALDH1A1TDP1NPSR1CA12 | |
| SCHEMBL1726101 | 0.84 | TSHR (0.59) | TSHRALDH1A1TDP1NPSR1CA12 | |
| SCHEMBL13689024 | 0.84 | TSHR (0.59) | TSHRALDH1A1TDP1NPSR1CA12 | |
| SCHEMBL18347983 | 0.84 | RAB9A (0.50) | TSHRALDH1A1NPSR1CA12CA1 | |
| SCHEMBL9911466 | 0.84 | RAB9A (0.54) | TSHRALDH1A1NPSR1CA12CA1 | |
| SCHEMBL13588790 | 0.83 | TDP1 (0.61) | TSHRALDH1A1TDP1CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY (US) | 2024-07-18 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024030651-A1 | GPX4 INHIBITORS AND USE THEREOF | SONATA THERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | MERCK HEALTHCARE KGAA (DE) | 2024-01-25 | — | — | US | disclosed |
| WO-2023196975-A1 | COMPOUNDS THAT INTERACT WITH RAS SUPERFAMILY PROTEINS FOR TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, LLC (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3870573-B1 | FUNCTIONALIZED AMINOTRIAZINES | LEADXPRO AG (CH) | 2023-08-02 | — | — | EP | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-7608618-B2 | Urea or thiourea substituted 1,4-pyrazine compounds useful as anti-cancer agents and for inhibiting Chk1 | ICOS CORPORATION (US) | 2009-10-27 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-25 | — | — | US | disclosed |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| US-7449465-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-11 | — | — | US | disclosed |
| US-7449465-B2 | Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2008-11-11 | — | — | US | disclosed |
| US-7358250-B2 | Pyrrolo[2,3-d]pyrimidines that modulate ACK1 activity | AMGEN INC. (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049603-A1 | Raf inhibitor compounds and methods of use thereof | BRAF, RAF1, ARAF | TSHR 3165/4885ALDH1A1 1842/4885TDP1 907/4885 |
| US-20240239774-A1 | SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF | UACA, ADCYAP1R1, ADCY1 | TSHR 1060/4885ALDH1A1 638/4885TDP1 2510/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | TSHR 3628/4885ALDH1A1 2932/4885TDP1 710/4885 |
| US-20240025922-A1 | TETRAHYDROPYRIDO[3,4-d]PYRIMIDINES AS HPK1 INHIBITORS | PDXK, DTYMK, HIPK1 | TSHR 3945/4885ALDH1A1 3576/4885TDP1 462/4885 |
| US-20080318929-A1 | Pyrimidine Derivatives Useful as Inhibitors of Pkc-Theta | PRKCQ, PRKCZ, PRKAR2B | TSHR 1657/4885ALDH1A1 4142/4885TDP1 182/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | TSHR 1602/4885ALDH1A1 1079/4885TDP1 1869/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | TSHR 3628/4885ALDH1A1 2932/4885TDP1 710/4885 |
| US-20080279867-A1 | Prevent trabsplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | TSHR 44/4885ALDH1A1 3232/4885TDP1 1500/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | TSHR 2111/4885ALDH1A1 411/4885TDP1 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.